CIK 0002058707 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Attovia Therapeutics, Inc.
Sign in to watch- Ticker
- ATTO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 921510574
- Phone
- 5103995001
- Business address
- 1091 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −672 | $22.02 | $15K | 74,870 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −6,970 | $22.03 | $154K | 67,900 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −400 | $22.02 | $9K | 67,500 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −1,180 | $21.84 | $26K | 66,320 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −1,040 | $22.05 | $23K | 65,280 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −300 | $20.84 | $6K | 64,980 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −443 | $21.78 | $10K | 64,537 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −200 | $22.05 | $4K | 64,337 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −700 | $22.07 | $15K | 63,637 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −1,163 | $22.19 | $26K | 62,474 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −100 | $21.99 | $2K | 62,374 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −6,763 | $21.61 | $146K | 55,611 |
| 2026-08-05 | GOLDMAN SACHS GROUP INC Former 10% Owner | Sale | −76,418 | $21.04 | $1.6M | 0 |
| 2026-08-04 | Chan Steven Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-08-04 | Fu Tao President and CEO | Grant or award · Stock Option (Right to Buy) | +538,300 | 538,300 | ||
| 2026-08-04 | Chen Hubert Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-08-04 | Veiby Petter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-08-04 | Odrowaz Zaneta Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-08-04 | GOLD MITCHELL Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-08-04 | You Angie Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 |
Page 8 of 9 · 162 trades